# A Risk Score Model Based on Drug-Sensitivity-Related Genes Has the Potential to Predict Oral Squamous Cell Carcinoma Prognosis

**Authors:** Yao Ma, Yunpeng Li, Sasa Ding, Peipei Sun

PMC · DOI: 10.3290/j.ohpd.c_2124 · Oral Health & Preventive Dentistry · 2025-08-05

## TL;DR

This study creates a risk score model using specific genes to predict the prognosis of oral squamous cell carcinoma patients.

## Contribution

A novel risk score model using four drug-sensitivity-related genes for predicting oral cancer prognosis is proposed.

## Key findings

- The model uses IGF2BP2, PLAU, CEP55, and CMYA5 to predict patient outcomes independently of age, gender, and stage.
- High-risk patients showed higher TP53 mutation rates and distinct immune infiltration patterns.
- A nomogram model was developed for personalized survival prediction based on risk score and age.

## Abstract

To develop a risk score model based on drug-sensitivity-related genes to predict the prognosis of patients with oral squamous cell carcinoma (OSCC).

In this study, transcriptome from OSCC patients was downloaded from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases, and differential gene expression analysis was performed using R’s ‘limma’ package. LASSO Cox regression identified key prognostic genes. We stratified patients into low- and high-risk groups and estimated survival rates using Kaplan-Meier. Gene set enrichment analysis (GSEA) and immune infiltration analysis were conducted to understand the potential pathways and tumour microenvironment. A nomogram model was constructed for prognosis prediction.

Our study identified 118 candidate genes from three data sets and narrowed them down to four prognostic genes (IGF2BP2, PLAU, CEP55, CMYA5) using univariate Cox regression and LASSO Cox regression. A risk score model was developed which could predict patient prognosis. The model’s prognostic value was independent of age, gender, and stage. A nomogram model incorporating risk score and age was constructed for personalised survival prediction. Tumour mutation burden analysis showed that the mutation rate of TP53 was higher in the high-risk group. Immune landscape analysis uncovered distinct immune cell infiltration patterns and immune checkpoint expression levels between different risk groups, suggesting implications for immunotherapy strategies.

The risk score model constructed using drug-sensitivity-related genes IGF2BP2, PLAU, CEP55, and CMYA5 may predict the prognosis of OSCC patients.

## Linked entities

- **Genes:** IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644], PLAU (plasminogen activator, urokinase) [NCBI Gene 5328], CEP55 (centrosomal protein 55) [NCBI Gene 55165], CMYA5 (cardiomyopathy associated 5) [NCBI Gene 202333], TP53 (tumor protein p53) [NCBI Gene 7157]
- **Diseases:** oral squamous cell carcinoma (MONDO:0004958)

## Full-text entities

- **Genes:** CEP55 (centrosomal protein 55) [NCBI Gene 55165] {aka C10orf3, CT111, MARCH, URCC6}, IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644] {aka IMP-2, IMP2, VICKZ2}, CMYA5 (cardiomyopathy associated 5) [NCBI Gene 202333] {aka C5orf10, SPRYD2, TRIM76}, PLAU (plasminogen activator, urokinase) [NCBI Gene 5328] {aka ATF, BDPLT5, QPD, UPA, URK, u-PA}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** OSCC (MESH:D000077195), Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12327071/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12327071/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12327071/full.md

---
Source: https://tomesphere.com/paper/PMC12327071